echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Treating a variety of neurological diseases about 2.6 billion US dollars to help develop selective GPCR agonists

    Treating a variety of neurological diseases about 2.6 billion US dollars to help develop selective GPCR agonists

    • Last Update: 2021-12-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Neurocrine Biosciences and Sosei Heptares announced a strategic cooperation and licensing agreement to jointly develop new selective muscarinic receptor agonists for the treatment of schizophrenia, dementia and other neurological diseases


    Muscarinic receptors are essential for brain function and have been verified as drug targets for psychosis and cognitive impairment


    Based on this platform, the company has discovered a variety of selective muscarinic M4, M1 and M1/M4 dual agonists, which have potential therapeutic effects while avoiding the harmful side effects caused by non-selective agonists


    According to the agreement, Neurocrine Biosciences will obtain the right to develop and commercialize the new selective muscarinic M4, M1 and dual M1/M4 receptor agonists discovered by Sosei Heptares


    In addition to the M1 agonist being developed in Japan, Neurocrine Biosciences will be responsible for development costs related to global R&D projects


    Reference materials:

    [1] Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders.


    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.